BRD4 expression, like IGF2BP3, was higher in tumor metastases than in primary tumors or normal tissues in both the TCGA pan-cancer and TNM skin cancer cohorts (Supplementary Figure S15b). This evidence concerns the gene IGF2BP3 and skin cancer.